DC-CIK细胞免疫治疗胃癌的临床疗效及预后分析

发布时间：2018-07-29 17:51

【摘要】：目的:回顾性分析自体DC联合CIK(DC-CIK)细胞治疗96例胃癌患者的临床疗效和安全性。方法:采集2011年8月至2016年4月解放军第86医院肿瘤科及解放军第81医院肿瘤生物治疗中心收治的96例胃癌患者的外周血单核细胞(peripheral blood mononuclear cell,PBMC),经实验室体外诱导培养DC和CIK细胞,DC通过胃癌MGC-803细胞裂解物致敏后与CIK细胞回输给患者,观察DC-CIK细胞治疗胃癌患者的临床疗效和安全性。结果:96例胃癌患者经DC-CIK细胞免疫治疗后,客观反应率为15.6%,疾病控制率为55.2%;1年生存率为56.0%,36~56个月总生存率维持在37.0%。免疫细胞治疗前后患者外周血肿瘤标志物CEA、CA199和CA724值均无明显变化。细胞治疗后患者外周血CD4~+CD25~+细胞比例显著下降[(3.22±1.20)%vs(2.46±1.04)%,P0.01],CD3~+、CD4~+、CD8~+、CD3~+CD56~+细胞百分比及CD4~+/CD8~+比值均无显著变化(P0.05)。单因素分析显示,TNM分期、细胞治疗次数、治疗前CEA和CA199值为DC-CIK治疗胃癌预后的影响因素(P0.05);多因素分析显示,细胞治疗次数、治疗前CEA和CA199值与DC-CIK细胞治疗胃癌患者的预后相关(P0.05)。结论:DC-CIK细胞免疫治疗对于胃癌患者是一种安全有效的治疗方式,多次治疗可能提高患者远期生存率。
[Abstract]:Objective: to retrospectively analyze the clinical efficacy and safety of autologous DC combined with CIK (DC-CIK) cells in the treatment of 96 patients with gastric cancer. Methods: from August 2011 to April 2016, 96 patients with gastric cancer were collected from Oncology Department of 86th Hospital of PLA and Cancer Biotherapeutic Center of 81st Hospital of PLA. Peripheral blood mononuclear cells (PBMCs) were collected and cultured in vitro. Cultured DC and CIK cell DC were sensitized by MGC-803 cell lysate of gastric cancer and then infused with CIK cells. To observe the clinical efficacy and safety of DC-CIK cells in the treatment of gastric cancer. Results after DC-CIK cell immunotherapy, the objective reaction rate was 15.6, the disease control rate was 55.2, and the 1-year survival rate was 56.0 ~ 56 months, and the overall survival rate was 37.00.Results after DC-CIK cell immunotherapy, the objective reaction rate was 15.6%, the disease control rate was 55.2%, and the 1-year survival rate was 56.0%. Before and after immunocytic therapy, there were no significant changes in serum tumor markers CEACA199 and CA724. After cell therapy, the percentage of CD4 ~ CD25 ~ cells in peripheral blood was significantly decreased [(3.22 卤1.20) vs (2.46 卤1.04) P 0.01] the percentage of CD3 ~ + CD4 ~ + CD8 ~ + CD56 ~ cells and the ratio of CD4 ~ / -CD8 ~ were not significantly changed (P0.05). Univariate analysis showed that TNM staging, cell therapy times, CEA and CA199 were the influencing factors for the prognosis of gastric cancer treated with DC-CIK (P0.05); multivariate analysis showed that the number of cell therapy, CEA and CA199 were correlated with the prognosis of patients with gastric cancer treated with DC-CIK cells (P0.05). Conclusion: the cell immunotherapy is a safe and effective method for gastric cancer patients, and multiple treatments may improve the long term survival rate of gastric cancer patients.
【作者单位】：解放军第86医院肿瘤科;解放军第81医院肿瘤生物治疗中心;
【基金】：南京军区面上课题基金资助(No.15ms 077)~~
【分类号】：R735.2

【相似文献】